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Practitioner Feedback on Lung Cancer Practice Guidelines
in Ontario
William K. Evans, MD,*¶ Ian D. Graham, PhD,† David Cameron, PhD (A.B.D.),‡
Jean A. Mackay MA,‡ and Mellissa Brouwers, PhD§
Purpose: Practitioner feedback (PF) surveys are sent to practitioners
who care for lung cancer patients as each new practice guideline is
completed. In this study, the PF was reviewed to assess the fre-
quency of response to the surveys, the respondents’ characteristics,
the nature of the feedback, and the intention to adopt the guideline
in practice.
Methods: Fourteen practice guidelines (PGs) were sent to Ontario
practitioners treating lung cancer, and feedback on the PGs was
obtained through either an eight- or 21-item survey.
Results: Between 1995 and 2002, 1198 surveys were sent to 223
practitioners. The overall response rate was 58.9% but varied by
specialty (radiation and medical oncologists, 67%; thoracic sur-
geons, 46%; respirologists, 38%), by location of practice (cancer
center, 65%; community-based practice, 55%), by geographic region
of the province (highest, 72%; lowest, 42%), and by PG topic
(chemotherapy, 60%; radiotherapy, 63%; combined modality ther-
apy, 52%). The response rate to the PF surveys did not decline over
time. Eighty-six percent of respondents agreed with the lung cancer
guidelines and indicated that they were likely or very likely to use
the PGs in their practice.
Conclusion: The results suggest that practitioners view the guide-
line development process as credible and useful to guide practice.
Whether the stated intention to use the guidelines will actually
translate into practice requires further study.
Key Words: Guidelines, Lung cancer, Survey, Practitioner feed-
back.
(J Thorac Oncol. 2006;1: 10–18)
Cancer Care Ontario (CCO) funds the Program in Evi-dence-Based Care (PEBC) to develop and maintain prac-
tice guidelines (PGs) that guide the practice of cancer care
providers in the province of Ontario, Canada. The PEBC,
sited at McMaster University, employs research coordinators
who facilitate the work of guideline panels (Disease Site
Groups [DSGs]) and working groups. Clinical practice guide-
lines are defined as systematically developed statements to
assist provider and patient decisions about appropriate health
care for specific clinical circumstances.1 Their development
through the PEBC follows the clinical practice guideline
development cycle, as previously described by Browman et
al.2 For clinical questions developed by members of the
DSGs, the research coordinators undertake systemic reviews
of the clinical literature. Electronic databases including
MEDLINE, CANCERLIT, the Cochrane Library and, more
recently, EMBASE, are systematically searched, as are Web-
based directories of existing guidelines, such as the National
Guidelines Clearinghouse. Proceedings of major meetings are
hand searched, as are reference lists of relevant articles and
review articles. The evidence is gathered predominantly from
English language peer-reviewed literature and summarized in
a standardized format. This information is reviewed and
thoroughly discussed by medical experts at DSG meetings.
Through this process, a draft guideline report is created that
incorporates the guideline question(s), the literature search
strategy, a systematic review of the scientific evidence, the
DSG consensus on the interpretation of the evidence, and
draft guideline recommendations. This document and a stan-
dardized feedback survey are then sent out for external
review to a wider group of physicians to whom the guideline
topic may be of interest. This process is referred to as
practitioner feedback (PF) and is the subject of this report.
The present study was undertaken to evaluate the re-
sponses of lung cancer care providers to the draft reports
developed by the Lung Cancer DSG (LDSG) between 1996
and 2002 through the PF component of the practice guideline
development cycle. Survey response rates were examined
over time and assessed against respondent characteristics.
Respondents’ perceptions of the draft PGs and their inten-
tions to use the guidelines were also examined.
METHODS
The LDSG of the PEBC currently consists of 32 indi-
viduals, including thoracic surgeons, radiation oncologists,
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medical oncologists, a medical sociologist, nurses, research
coordinators, and a methodologist. The LDSG, chaired by
one of the authors of this article (W.K.E.), has worked to
develop practice guidelines since 1995. The methodology for
developing practice guidelines through the PEBC has been
described previously,2 and this approach to guideline devel-
opment has been followed by the LDSG for all PGs devel-
oped to date. Some of the lessons learned from the early years
of practice guideline development by the LDSG have been
described previously.3
Over an 8-year period (1995–2002), the 14 LDSG
reports summarized in Table 1 underwent PF and are the
subject of this report.4–16 One PG sent out for PF was never
published but was entirely rewritten after PF and became PG
7-7-1, the role of taxanes in first-line therapy of advanced
non–small-cell lung cancer (NSCLC). The PF for this PG had
not been completed at the time of the PF analysis for this
article. Four additional documents have been published17 or
are submitted for publication and 12 are in preparation by the
LDSG.
The LDSG has produced or is currently developing
PGs for all stages of NSCLC,4–9,11,12,15,16 small-cell lung
cancer, 10,13,14 and mesothelioma, and on the use of particular
modalities, such as high-dose-rate brachytherapy, photody-
namic therapy,17 and altered radiation fractionation sched-
ules.11 In addition, the pathology members of the LDSG
developed a guideline on the handling and reporting of lung
cancer specimens.18
Survey Instruments
In 1995, an eight-item practitioner survey was devel-
oped to assess whether practitioners found the draft guide-
lines to be clear, relevant, and complete. The survey ques-
tions are listed in Table 2. In particular, the survey asked
whether the literature search was complete and the summary
of evidence acceptable. Importantly, it asked whether the
recommendations should serve as a practice guideline and
whether the practitioner would use the guideline in practice.
Although useful in some respects, this survey was not
grounded in any credible theoretical framework and the
PEBC was not gathering data on issues now known to be
important for knowledge transfer and application. Therefore,
a new 21-item survey was developed.19 The new survey is
composed of items that are successful at predicting clinicians’
endorsement of a draft guideline and their intentions to use
the guideline in practice (Table 3).
In this study, data are presented from 387 surveys using
the eight-item survey to elicit physicians’ views of eight draft
PGs and 212 surveys using the 21-item survey eliciting
feedback on seven of the draft PGs. It must be noted that for
one draft PG, 7-13-3, physicians were randomized to receive
either the eight- or 21-item survey to investigate the impact of
the longer instrument on response rates.
Most guidelines were sent to all Ontario lung cancer
care providers in the database maintained by the PEBC,
which includes medical and radiation oncologists, thoracic
surgeons, and respirologists; however, in a few cases, the
guideline was only sent to medical or radiation oncologists if
the document was highly technical and likely to be of interest
and relevance to only one group of specialists. Each guideline
was sent with a covering letter and the survey instrument. In
most cases, individual practitioners were sent more than one
draft guideline and PF survey package over this time period.
TABLE 1. Guidelines Sent for Practitioner Feedback
Guideline No. Topic Published Posted on Web Site PF Report Date
7-2 Chemotherapy for NSCLC Yes Yes 1995
7-5 Vinorelbine in NSCLC Yes Yes 1995
7-3 Unresected stage III NSCLC Yes Yes 1996
7-1 Postoperative XRT and/or chemotherapy in NSCLC Yes No* 1997
7-4 Preoperative chemotherapy  XRT for stage IIIA NSCLC Yes Yes 1997
7-8 Gemcitabine in NSCLC Yes No† 1997
7-13-3 Thoracic XRT for SCLC Yes Yes 1998
7-12 Altered XRT fractionation for NSCLC Yes Yes 1999
7-13-2 PCI for SCLC Yes Yes 1999
7-7 Paclitaxel as first-line therapy for NSCLC No No‡ 2000
7-7-2 Docetaxel as second-line therapy in NSCLC Yes Yes 2000
7-13-1 Combination chemotherapy Yes Yes 2000
for limited SCLC
7-1-1 Postoperative XRT in NSCLC Yes Yes 2001
7-8 2002 Gemcitabine as first-line therapy for NSCLC Yes Yes 2002
*Replaced by guideline 7-1-1. †Replaced by guideline 7-8 2002. ‡After PF was obtained, this guideline was revised to include docetaxel and was repackaged as guideline 7-7-1.
PF, practitioner feedback; XRT, radiotherapy; NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; PCI, prophylactic cranial irradiation.
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The covering letter from the leadership of the PEBC indicated
that the practitioner had been identified as someone for whom
the guideline might be relevant and invited their participation
in reviewing the guideline. In addition to responding to the
survey questions, practitioners were given the opportunity to
make comments and suggestions to improve the document.
For the purposes of this analysis, comparable questions
from the two survey instruments were combined where ap-
propriate. Descriptive data are presented and statistical anal-
yses of the data have not been conducted because the number
and types of practitioners surveyed with each PF varied. Also,
surveys were applied to a variety of different types of guide-
lines including some that were focused exclusively on radio-
therapy or systemic therapy topics, whereas others involved
combined modality therapy.
RESULTS
A total of 1198 PF surveys were sent to 223 practi-
tioners between 1995 and 2002. Of these, 181 surveys from
18 individuals were excluded from the analysis because they
were deemed ineligible (153 surveys were returned without
being completed, as the topic of the guideline was not
relevant to the physician’s practice and another 28 surveys
were returned by individuals who had retired, were on sab-
batical, or had moved and had no forwarding address). When
these ineligible surveys were excluded, 1017 surveys sent to
205 participants formed the basis of the analysis. The overall
survey response rate was 58.9% (599 of 1017 surveys).
Respondent characteristics and the PF response rates are
summarized in Table 4 and described below.
Specialty
Of the 205 practitioners surveyed, 38% (77 of 205)
were medical oncologists (including hematologists), 18% (37
of 205) were radiation oncologists, 24% (49 of 205) were
thoracic surgeons, 18% (37 of 205) were respirologists, and
2% (five of 205) did not indicate their specialization. The rate
of response differed by the specialty of the respondent, with
medical and radiation oncologists as a group having a higher
response rate than surgeons and respirologists. Altogether,
67% of the surveys sent to medical (95% confidence interval
[CI], 63–71%) and radiation oncologists (95% CI, 60–74%)
were completed and returned (360 and 109 returned surveys,
respectively). Forty-six percent (95% CI, 38–53%) of the
surveys sent to thoracic surgeons, 38% (95% CI, 30–47%) of
the surveys sent to respirologists, and 18% (95% CI, 0–38%)
of the surveys sent to respondents of unknown specialization
were completed and returned (72, 55, and three surveys
returned, respectively). The mean response rates for the
individuals in medical oncology/hematology, radiation oncol-
ogy, thoracic surgery, and respirology were 58% (95% CI,
48–67%), 67% (95% CI, 55–80%), 43% (95% CI, 30–55%),
and 37% (95% CI, 24–50%), respectively.
TABLE 2. Initial Eight-Item Practitioner Survey,
1995–1999*
1. Is the recommendation relevant to your practice? (Yes or no. If yes,
then continue with items 2–8.)
2. The rationale for developing this evidence-based recommendation, as
stated in the “Choice of Topic” section of the report is clear.
3. A practice guideline on this topic will be useful to clinicians.
4. The literature search is relevant and complete (i.e., no key trials were
missed nor any included that should not have been. The methods are
adequately described).
5. The summary of the evidence is acceptable to me (i.e., data extraction
is accurate. The results of the trials are interpreted according to my
understanding of the data).
6. I agree with this evidence-based recommendation as stated.
7. In your opinion, this recommendation should serve as a practice
guideline.
8. If this evidence-based recommendation were to become a practice
guideline, would you use it in your own practice?
*For items 2 through 7, possible responses are as follows: “strongly agree,”
“agree,” “neither agree nor disagree,” “disagree,” or “strongly disagree.” For item 8,
possible responses are as follows: “yes,” “no,” or “unsure.” For “no” or “unsure”
responses, additional comments are requested.
TABLE 3. Twenty-One–Item Practitioner Survey,
1999 Onward*
1. Are you responsible for the care of patients for whom this practice-
guideline-in-progress (PGIP) report is relevant? (Yes or no. If yes,
please answer the questions below.)
2. The rationale for developing a CPG as stated in the “Choice of Topic”
section of the report, is clear.
3. There is a need for a CPG on this topic.
4. The literature search is relevant and complete (i.e., no key trials were
missed nor any included that should not have been) in this PGIP report.
5. I agree with the methodology used to summarize the evidence included
in this PGIP report.
6. The results of the trials described in the PGIP report are interpreted
according to my understanding of the data.
7. The DRs in this report are clear.
8. I agree with the DRs as stated.
9. The DRs are suitable for the patients for whom they are intended.
10. The DRs are too rigid to apply to individual patients.
11. When applied, the DRs will produce more benefits for patients than
harms.
12. The PGIP report presents options that will be acceptable to patients.
13. To apply the DRs will require reorganization of services in my
practice setting.
14. To apply the DRs will be technically challenging.
15. The DRs are too expensive to apply.
16. The DRs are likely to be supported by a majority of my colleagues.
17. If I follow the DRs, the expected effects on patient outcomes will be
obvious.
18. The DRs reflect a more effective approach for improving patient
outcomes than is current usual practice (if DRs are the same as usual
practice, please tick NA).
19. When applied, the DRs will result in better use of resources than
current usual practice (if DRs result in the same outcomes as usual
practice, please tick NA).
20. This PGIP report should be approved as a practice guideline.
21. If the PGIP report were to become a practice guideline, how likely
would you be to make use of it in your own practice?
*For items 2 through 20, possible responses are as follows: “strongly agree,”
“agree,” “neither agree nor disagree,” “disagree,” or “strongly disagree.” For item 21,
possible responses are as follows: “not at all likely,” “unlikely,” “unsure,” “likely,” or
“very likely.” CPG, clinical practice guideline; DRs, draft recommendations; NA, not
applicable.
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DSG Membership
Membership on one of the CCO DSGs did not significantly
affect the PF survey response rates, although non-DSG members
did have a lower response rate as a group. Of the 205 respondents,
21 (10%) were DSG members, 183 (89%) were not, and one
individual was a DSG member for part of the study period. Sixty-
one percent (95% CI, 52–70%) of the surveys sent to DSG mem-
bers were returned (69 returned surveys) compared with 59% (95%
CI, 55–62%) of surveys sent to non-DSG members (530 returned
surveys). The mean response rates were 59% (95% CI, 41–77%)
for individuals who were DSG members (n 22) and 50% (95%
CI, 44–57%) for non-DSG members (n 183). It is important to
note that midway through the time period of this study, members of
the LDSG were no longer eligible to serve as practitioner feedback
participants, as they contributed to the creation of the document
being evaluated.
Location of Practice
There was significant variation in response rate by
physicians’ practice location. Of the 204 who indicated their
practice location, 82 (40%) reported practicing exclusively in
a regional cancer center (RCC) or Princess Margaret Hospital
(PMH) and 122 (60%) reported practicing exclusively in the
community. Sixty-five percent (95% CI, 60–69%) of the
surveys sent to the physicians practicing at an RCC/PMH
were returned (n  259 completed surveys) compared with
55% (95% CI, 51–59%) of the surveys sent to physicians who
practiced in the community (n  339 completed surveys).
The mean response rates of the individuals practicing at an
RCC/PMH and in the community were 61% (95% CI, 52–
71%) and 44% (95% CI, 36–52%), respectively.
Geographic Region of the Province of Ontario
Of the 205 participants, five reported different geo-
graphic regions of the province of Ontario on at least two
surveys that they returned. For the purpose of this report, a
region was identified by the name of the major city in which
a cancer center was located. The respondents in a region
represented the practitioners involved in the care of lung
cancer patients from the cancer center, the adjacent hospital
TABLE 4. Respondent Characteristics and Practitioner Feedback Response Rates
No. of
Unique
Respondents
No. Responding
to At Least One
Survey
Proportion of
Respondents
Returning At
Least One
Survey
Mean Response
Rate for
Individuals in
Category
(95% CI)
No. of
Surveys Sent
No.
Returned
Response Rate
for Group
(95% CI)
Specialty
Med onc/hem 77 56 73 58(48–68) 536 360 67(63–71)
Rad onc 37 32 86 67(55–80) 163 109 67(60–74)
Surgeon 49 27 55 43(30–55) 158 72 46(38–53)
Respirologist 37 20 54 37(24–50) 143 55 38(30–47)
Other 5 1 20 20 (6–51) 17 3 18 (0–38)
DSG membership*
Yes 21 17 77 59(41–77) 113 69 61(52–70)
No 183 119 65 50(44–57) 904 530 59(55–62)
Practice setting†
RCC or PMH 82 64 78 61(52–71) 400 259 65(60–69)
Community 122 71 58 44(36–52) 616 339 55(51–59)
Region‡
Windsor 13 8 62 44(18–71) 70 43 61(50–73)
London 27 20 74 57(41–74) 130 77 59(51–68)
Hamilton 21 16 76 61(42–80) 120 86 72(63–80)
Toronto 57 42 74 58(46–69) 326 224 69(64–74)
Kingston 13 6 46 45(14–76) 39 22 56(40–73)
Ottawa 34 22 65 44(30–59) 202 84 42(35–48)
Sudbury 9 7 78 51(19–82) 49 23 47(32–61)
Thunder Bay 8 5 63 51(14–88) 36 20 56(39–73)
Unknown 23 10 43 38(18–58) 45 20 44(29–60)
CPG type
Chemotherapy 122 75 61 54(45–62) 384 230 60(55–65)
Radiation therapy 162 105 65 53(46–60) 382 239 63(58–67)
Combined Modality 128 69 54 52(44–61) 251 130 52(46–58)
*One respondent indicated that he/she was a DSG member and a non-DSG member on different surveys. For the analysis, this person was classified as being a DSG
member.†Three respondents indicated different locations on different surveys and for the analysis were classified as practicing at an RCC. One respondent did not indicate practice
setting and was excluded from the analysis, making the total number for this variable 204. ‡5 respondents were practicing in two regions when surveyed and for the analysis were
classified under the region reported on the first survey. Med onc, medical oncologist; hem, hematologist; rad onc, radiation oncologist; DSG, Disease Site Group; CPG, clinical
practice guideline; CI, confidence internal; RCC, regional cancer center; PMH, Princes Margaret Hospital.
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facilities, and any community-based practitioners in the
catchment area served by the cancer center. The response rate
by geographic region varied from a low of 42% (95% CI,
35–48%) for the Ottawa region, to a high of 72% (95% CI,
63–80%) for the Hamilton region. The respondents for whom
information on the region in which they practiced was un-
available also had a low response rate of 44% (95% CI,
29–60%). The mean response rate for the individuals iden-
tified by each region were as follows: Windsor, 44% (95%
CI, 18–71%); London, 57% (95% CI, 41–74%); Hamilton,
61% (95% CI, 42–80%); Toronto, 58% (95% CI, 46–69%);
Kingston, 45% (95% CI, 14–76%); Ottawa, 44% (95% CI,
30–59%); Sudbury, 51% (95% CI, 19–81%); Thunder Bay,
51% (95% CI, 14–88%); and region unknown, 38% (95%
CI, 18–58%).
Response Rates By Guideline Topic
When the response rate was examined by PG topic,
there was a difference in response rates. The response rates
were 60% (95% CI, 55–65%) for chemotherapy guidelines,
63% (95% CI, 58–67%) for radiation therapy guidelines, and
52% (95% CI, 46–58%) for combination therapy guidelines
(Table 5). This difference was not present when we examined
the mean response rate of individuals. An individual was
equally likely to respond if they were sent a chemotherapy,
radiation therapy, or combined modality therapy PG. The
mean response rate for individuals receiving one or more
chemotherapy guidelines was 54% (95% CI, 45–62%) com-
pared with 53% for those receiving radiotherapy PGs (95%
CI, 46–60%) and 52% (95% CI, 44–61%) for individuals
who received combined modality PGs.
Response Rates Over Time and Responder Fatigue
To examine whether responder fatigue occurred, we
assessed the response rate for each guideline by the year in
which it was released (Table 5). This demonstrated that,
although the response to the PF surveys has varied over time,
there has been no consistent trend. The response rates ranged
from a low of 48% for a guideline on the role of gemcitabine
in NSCLC (PG 7-8), which was written when the fully
published evidence was limited, to a high of 81% for a
practice guideline on the role of locoregional radiotherapy in
the management of small-cell lung cancer (PG 7-13-3).
Individual practitioners received between one and 14
different draft guidelines and feedback survey packages, with
an average of just over five draft guidelines per practitioner.
Of the 205 individuals, 136 (66.3%) returned at least one
survey they had been sent. Nearly 34% of participants (69 of
205) returned all PF surveys that they were sent; 8.4% (17
of 205) returned more than 75% of their surveys; 12% (25 of
205) returned between 50% and 75%; 12% (25 of 205)
returned less than half, and 34% (69 of 205) did not return
any of their surveys. The mean individual response rate per
physician was 51%.
To examine the relationship between response rate and
the number of surveys a participant was sent, we divided the
205 participants into quartiles on the basis of the number of
surveys they had been sent. The mean response rates were
44% (range, 32–56%), for the 63 individuals who received
one to two CPGs, 52% (range, 39–64%) for the 45 individ-
uals who received three to four surveys, 40% (range, 28–
51%) for the 48 individuals who received five to six surveys,
and 72% (range, 62–81%) for the 49 individuals who re-
ceived seven to 14 surveys. These data failed to reveal a
direct inverse relationship between number of guidelines sent
to an individual and their response rate and actually demon-
strated that the response rate was highest for physicians
receiving the most guidelines on which to provide PF.
Changes in Physicians’ Perceptions of the
Draft PGs Over Time
An essential aspect of the PF process is to seek, in an
ongoing fashion, individual practitioners’ opinions on new
TABLE 5. Practitioner Response Rate by CPG Topic and Year CPG Completed
CPG Date of Release Type of CPG No. of Surveys Sent No. Returned Response Rate for Group (%) 95% CI (%)
7-2 February of 1996 Chemo 96 55 57 47–67
7-5 August of 1996 Chemo 89 52 58 48–69
7-3 March of 1997 Rad 98 63 64 55–74
7-1 September of 1997 CMT 126 67 53 44–62
7-4 September of 1997 CMT 125 63 50 42–59
7-8 October of 1998 Chemo 56 27 48 35–62
7-12 October of 1999 Rad 70 40 57 45–69
7-13-3 October of 1999 Rad 53 43 81 70–92
8-item survey 26 20 77 60–94
21-item survey 27 23 85 71–100
7-7 February of 2000 Chemo 36 24 67 50–83
7-13-2 March of 2000 Rad 72 46 64 53–75
7-7-2 January of 2001 Chemo 36 27 75 60–90
7-13-1 March of 2001 Chemo 36 24 67 50–83
7-8 2002 September of 2002 Chemo 35 21 60 43–77
7-1-1 September of 2002 Rad 89 47 53 42–63
Chemo, chemotherapy; Rad, radiation therapy; CMT, combined modality therapy.
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draft guidelines. Although it is recognized that specific indi-
vidual practitioners may tend to generally like or dislike
certain types of recommendations across guidelines, it is
believed that each individual guideline is sufficiently unique
to allow for the examination of all PF data combined. Be-
cause of this, a general pooling of attitudes across and
between guidelines was felt to be sufficient although, strictly
speaking, a mixed-effects statistical model of explanation
would be the most appropriate way to take individual pref-
erences into account. The remainder of this report does not
specifically take practitioner-level variance into account.
Over the study period, five items were used to assess
respondents’ perceptions of the characteristics of the draft
guidelines in both versions of the PF questionnaires. In some
cases, the wording of the items differed slightly between the
eight- and 21-item survey and the alternative wording is
noted in brackets below. Overall, 87% of respondents agreed
or strongly agreed that the draft guideline would be useful to
clinicians (guideline needed on the topic), 96% considered
the rationale for developing the evidence-based recommen-
dations to be clear, 91% considered the literature search
relevant and complete, 94% considered the summary of the
evidence acceptable (agreed with the methodology used to
summarize the evidence), and 86% agreed with the evidence-
based recommendation (agreed with the draft recommenda-
tion as stated).
As shown in Figure 1, the proportion of respondents
indicating that they agreed or strongly agreed that the ratio-
nale for developing the evidence-based recommendations
was clear, the literature search relevant and complete, and the
summary of the evidence acceptable has differed little over
time. However, there has been a downward trend in the
proportion of respondents agreeing that there was a need for
a specific CPG and an upward trend in those agreeing with
the recommendations.
Practitioners frequently provided written comments on
issues of guideline clarity or suggested changes to the word-
ing of the guideline recommendations. Occasionally, they
brought evidence to light that had not been identified through
the literature search process. Rarely, an alternative interpre-
tation of the data was presented. Concerns about the cost or
logistics of implementing a guideline recommendation were
common, particularly when the recommendation involved
new and expensive drugs. The feedback improved the quality
of the documents and, on occasion, led to a substantive
change. For example, the draft PG 7-1-1 recommended
against postoperative radiotherapy for stage II or IIIA
NSCLC; however, after PF, separate recommendations were
developed for each disease stage.15 All substantive comments
received were described in the final version of the guideline,
and an explicit statement was made as to how each of the
issues raised was addressed in the final document.
Intentions to Use the PGs
Between 1995 and 1999, the eight-item practitioner
survey specifically asked whether the practitioner would use
the practice guideline in their practice (question 8 of the
survey; response categories: yes, no, and unsure). Since
October of 1999, the 21-item practitioner survey asked re-
spondents how likely they were to make use of the guideline
in their practice if the draft PG report were to become a
practice guideline (question 21; response categories: not at all
likely, unlikely, unsure, likely, and very likely). To examine
possible changes in intentions to use guidelines over time, we
considered a yes to question 8 of the eight-item survey and a
response of either likely or very likely to question 21 of the
21-item survey as an indication of intention to use the
guideline. During the study period, 81% of all respondents
indicated that they intended to use the lung PGs in their
practices.
Over the study period, respondents’ intentions to use
the guidelines ranged from 65% (range, 50–80%) (PG 7-2) to
95% (range, 89–100%) (PG 7-13-2), with medical oncolo-
gists and surgeons more frequently indicating an intention to
use the guidelines in their practice than radiation oncologists
(Figure 2).
DISCUSSION
When the LDSG first convened to consider the devel-
opment of practice guidelines, the views expressed by the
oncologists invited to be members of the DSG were not
unlike the views of the respondents to the 1996 survey of
Taylor et al.20 Oncologists expressed concern that the guide-
lines represented “cookbook medicine,” and that they were
not relevant to all patients and were a potential straightjacket
applied to practitioners to curb costs. They also expressed
concern about whether such documents could be kept current
and were, in fact, useful.3
It is, therefore, encouraging to find that in the period
since 1995, practitioners providing feedback on draft PGs not
only acknowledged the need for a practice guideline on the
various topics in 87% of cases but found the summarized
evidence acceptable (94%) and agreed with the guideline
recommendations (86%). Furthermore, 81% of respondents
indicated that they were likely or very likely to use the lung
cancer PGs in their practice.
Practitioner feedback has been built into the PG cycle
for a number of reasons:
FIGURE 1. Practitioners’ perceptions of guideline character-
istics over time.
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1. The draft PG provides practitioners with a systematic
summary of the available information on a topic in an
organized and concentrated fashion with draft recom-
mendations for review. With the large and growing
number of publications and meetings, this knowledge
synthesis fulfils a valuable educational function, partic-
ularly for busy practitioners who have difficulty finding
time to keep up with the literature. Rather than simply
providing the information as an educational resource,
which might not be used, PF actively solicits the opin-
ion of the clinician on the document’s content, com-
pleteness, and accuracy. By requesting PF, physicians
have to take the time to review the information in the
document to be able to comment on it.
2. This review function helps to ensure that the document
is indeed complete, as practitioners access different
journals and travel to different meetings and may iden-
tify sources of information and perspectives on the data
not identified through the systematic review. It also
stimulates learning, and the time expended can be
applied toward continuing education credits.
3. The PF also serves a consultative function and gives
practitioners the opportunity to suggest changes to the
user group. Recommendations for changes to the doc-
ument are explicitly described in the final version of the
document so that those who have made suggestions for
change can see how their suggestions have been ad-
dressed. By providing an opportunity to non-DSG
members and members from other DSG groups to
review the evidence and the clinical recommendations,
a wider group of practitioners can be engaged in shap-
ing the final PG. It is rare that PF has changed the main
recommendations arising from the evidence. In con-
trast, practitioners have identified issues of accuracy
and clarity and have found inconsistencies between the
recommendations and the evidence itself. Indeed, in an
overall evaluation of the PF process across all DSGs of
the PEBC, it was found that despite a rigorous evi-
dence-based process for PG development, practicing
oncologists contributed to the final recommendations
included in 19 of the 43 PGs reviewed (44%).21 Of the
40 changes made, 28 were considered to be substantive
(70%), affecting the content (18 changes) or tone (10
changes) of the guideline recommendations. In addi-
tion, eight changes related to improvements in clarity
and four changes were editorial in nature.21 The PF
solicits potential user’s views on the potential use of the
guideline and identifies issues that might reduce the
uptake of the guideline.
4. Finally, the PF component of the practice guideline
cycle contributes to the dissemination of the guideline,
as it serves to give advance notice that a guideline is
about to be finalized. By providing the practitioner with
up-to-date evidence in support of a particular treatment
approach, the guideline has the potential to shape the
thinking of practitioners in the field on what constitutes
appropriate care, including the use of new drugs. A
guideline related to a new drug, for instance, alerts
practitioners to the fact that the drug will be recom-
mended to government for approval and funding. Prac-
titioner feedback is just one component of a multifac-
eted implementation strategy. Other implementation
strategies include publishing the PGs in peer-reviewed
journals, posting the PGs on CCO’s Web site, academic
detailing, and the conduct of best-practice workshops.
The ultimate goal of practice guideline development is
to transfer knowledge, packaged in the form of a guideline,
into clinical practice. The most efficient way(s) to accomplish
this transfer of knowledge is currently unknown. Grimshaw
and Eccles undertook a systematic review of guideline dis-
semination and implementation strategies and noted that the
majority of interventions produced only modest to moderate
improvements in care.22 For example, analyses of cluster
randomized trials showed a median absolute improvement in
care varying between 6.0% for multifaceted educational out-
reach interventions (13 trials) and 14.1% for reminder inter-
ventions (14 trials). Improvements of 8.1% and 7.0% were
observed for dissemination of educational materials (four
trials) and use of audit and feedback (five trials).22 From this
review, the logical conclusion is that there are no magic
bullets for improving the uptake of guidelines. Surveying the
directors of 265 Canadian health and economic research
organizations, Lavis et al. found that knowledge transfer is
most effective when researchers develop credible and action-
able messages, develop the knowledge-uptake capacity
among audiences, fine-tune their own knowledge transfer
skills, and undertake interactive evaluative measures to de-
termine whether the knowledge is being used.23 As suggested
by Lavis et al., it is likely that moving beyond a passive
“producer-push” approach to include more interactive ex-
change with users adds to the success of knowledge trans-
fer.23 The PEBC guideline implementation strategy attempts
to accomplish this, in part, through its efforts to actively
engage practitioners in the field through this feedback com-
ponent of the practice guideline development cycle.
Of significance, this review identified a relevant prac-
titioner population that is not being reached through the PF
process. We identified that the number of respirologists in the
database used for PF was small relative to the number of
FIGURE 2. Practitioners’ intentions to use CPGs by spe-
cialty over time.
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respirologists in the province of Ontario. Respirologists are
important gatekeepers who influence whether patients receive
treatment following an initial diagnosis of lung cancer. It is
important that this group of internal medicine specialists be
knowledgeable of the current guideline recommendations for
the care of lung cancer patients so that they refer patients
appropriately for care. The PEBC will review the PF database
and augment the database with the names of respirologists
and ensure that specialists in lung cancer systemic therapy,
radiotherapy, and thoracic surgery are included.
The results of this review of PF on 14 documents
developed by the LDSG indicate that the attitudes among the
practitioners responding to lung cancer PGs in Ontario are
positive toward practice guidelines. This is consistent with
the results of a national survey of Canadian oncologists
conducted by Graham et al.24 This survey found that over
80% of respondents felt that clinical PGs were good educa-
tional tools and convenient sources of advice and were
intended to improve care. Over 40% agreed that they were
unbiased syntheses of expert opinion and only 42%, 26%,
20%, and 16% felt they were intended to cut costs, were
oversimplified cookbook medicine, were too rigid to apply to
individual patients, and were a challenge to physicians’
authority, respectively. Interestingly, in this survey, positive
attitudes to PGs were associated with receiving medical
school training abroad and with being a radiation oncologist.
In Ontario, guidelines related to new and expensive drugs
have been linked to funding policies in the province25,26 and
enabled practitioners to gain access to therapies that might
otherwise have been denied to their patients if they were
dependent on local institutional decisions and pharmacy bud-
gets. This linkage between guidelines and funding policy may
contribute to the generally positive attitude toward PGs in the
Ontario setting, as PGs facilitate access to new drugs.
There are, however, limitations to our study of PF. In
the first place, the data on potential use of the guidelines in
practice is self-reported and may not reflect actual use of the
guideline. CCO has begun to produce Clinical Monographs
on practice in Ontario but is limited to describing practice in
its RCCs, as administrative databases outside of CCO do not
have the necessary information on tumor stage and treatment
regimens to assess consistency of practice with guideline
recommendations. Within CCO centers, practice variation
has been noted and is particularly evident in the chemother-
apeutic management of stage IV NSCLC (www.cancer-
care.on.ca). However, it is challenging to interpret these data.
Even if the practitioner intended to use a guideline in prac-
tice, there may be specific barriers to its implementation that
are not captured from data sets including information about
resource availability and patient willingness to accept care.
Our interpretation of the attitudes of practitioners to-
ward LDSG guidelines may also be subject to nonresponse
bias. In this study, the overall survey response rate was
almost 60%. It is possible that those practitioners who did not
respond or who responded only occasionally had a more
negative view toward guidelines and chose not to respond for
this reason. In contrast, it is also possible that practitioners
who did not respond were simply busy practitioners who
were grateful to receive the guidance documents but too busy
to take the time to carefully review the documents and
respond to the surveys.
The lower group response rate of community practitio-
ners to the questionnaire surveys (55%) compared with the
group response rate of RCC/PMH practitioners (65%) sug-
gests that the PEBC may not yet be engaging the community
practitioners in an optimal fashion. These practitioners may
also wish to have a greater degree of independence in their
practice and may see the development of practice guidelines
as a threat to their practice autonomy. In contrast, as sug-
gested above, they may be too busy in practice to respond to
surveys.
The difference in response rates between different geo-
graphic areas of the province is of interest. The highest group
rate of response was from the Hamilton area (72%), where
the PEBC is located. This may reflect the well-developed
culture of evidence-based practice associated with the cancer
center in Hamilton and at McMaster University. In contrast,
the lowest group rate of response was from Ottawa (42%),
where there is a strong culture of new drug development and
the early adoption of new therapies. Overall, however, it is
gratifying to see that the guidelines being developed by the
LDSG have a high degree of acceptability with practitioners
who respond to the surveys and that a substantial proportion
of these practitioners indicate that the PGs will form the basis
for the care of patients in their practice.
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